PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients- An Economical Analysis of a prospective Phase 2 Study (GFPC 0505)
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1180
https://www.valueinhealthjournal.com/article/S1098-3015(11)02742-2/fulltext
Title :
PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients- An Economical Analysis of a prospective Phase 2 Study (GFPC 0505)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02742-2&doi=10.1016/j.jval.2011.08.1180
First page :
A448
Section Title :
Cancer
Open access? :
No
Section Order :
1135